logo
Longevity enthusiast Bryan Johnson says he doesn't want to run his antiaging company anymore

Longevity enthusiast Bryan Johnson says he doesn't want to run his antiaging company anymore

Johnson was speaking to Wired's Katie Drummond in an interview published Monday, and he was asked about the conflicts that came with running his business and religion at the same time.
The 47-year-old biotech entrepreneur is best known for his aggressive quest for eternal youth. In 2021, Johnson embarked on his anti-aging program, Project Blueprint, which he says costs him $2 million a year.
At one point, Johnson infused himself with blood from his son to slow down his aging. He stopped the transfusions after six months, saying there were "no benefits detected."
Johnson's company sells a variety of wellness products. These include a $55 "longevity mix" drink and a $42 mushroom coffee alternative they call "Super Shrooms."
In March, Johnson announced on X that he was starting his own religion, "Don't Die." The name is derived from the slogan Johnson used to brand his Netflix documentary, products, and events.
"Years ago, I did a thought experiment imagining myself in the presence of people from the 25th century. It seemed obvious that they'd say Don't Die is how humanity saved itself and merged with AI," Johnson wrote in an X post.
Johnson, however, says he's beginning to see how running a longevity-focused business may not mesh with preaching a religion on the same subject.
"Honestly, I am so close to either shutting it down or selling it," he told Drummond, adding that he's "been talking to people about this."
"I don't need the money, and it's a pain-in-the-ass company," he said.
Johnson said he started the business because his friends were asking him for the health supplements he was taking.
"It just evolved in a way where I was trying to do people a solid. The problem is now people see the business and give me less credibility on the philosophy side," Johnson said.
"I will not make that trade-off. It is not worth it to me. So yeah, I don't want it," he added.
Earlier this year, The New York Times reported that Blueprint was facing problems with its finances. The story was published in March and was based on interviews with current and former employees as well as court records and internal documents.
The Times reported that Blueprint was missing its break-even point by at least $1 million a month.
Johnson told Wired Blueprint isn't in "some kind of emergency financial situation."
"We are break-even, and I've said that publicly many times. We've had profitable months, we've had loss months," he added.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

How Johnson & Johnson Stock (JNJ) Discovered a New Lease of Life
How Johnson & Johnson Stock (JNJ) Discovered a New Lease of Life

Business Insider

time4 hours ago

  • Business Insider

How Johnson & Johnson Stock (JNJ) Discovered a New Lease of Life

Biopharma giant Johnson & Johnson's (JNJ) stock hit new highs this year after reporting its Q2 results on July 16th, giving the market a clear signal that it's reigniting growth with practically flawless numbers—a potential turning point for the second half of the year. The upwardly revised guidance and expectations for strong margin expansion, despite lingering litigation concerns, have brought fresh optimism to the stock and appeased shareholders clamoring for added value. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. While the stock isn't as discounted as it was earlier this year, valuations still look reasonable. Given JNJ's strong compounding potential and this renewed bullish momentum, I see it as a Buy. How J&J's Strong Quarter Sets the Stage for Growth Johnson & Johnson stock has been rangebound for years, weighed down by a mix of factors, including a massive wave of lawsuits claiming its talc-based baby powder caused cancer due to asbestos contamination, as well as expiring drug patents, such as its blockbuster Stelara losing exclusivity. Last but not least is sluggish growth and an eroded safe-haven reputation, since legacy consumer brands like Tylenol, Listerine, and Band-Aid have low growth and face margin pressure from cheap competition. According to TipRanks data, JNJ has underperformed the S&P quite considerably since 2024. Johnson & Johnson's latest Q2 earnings may mark a true inflection point toward more consistent alpha generation. The company delivered exactly what it needed— beating both earnings and revenue expectations —while issuing a notable upward revision to guidance: an additional $2 billion in forecasted sales and $0.25 more in projected EPS. For a pharma giant like J&J, that's a clear signal of renewed momentum following a prolonged period of litigation-related overhang. Management also reaffirmed its full-year outlook for a 300-basis-point improvement in operating margin, raising it from approximately 25.4% to 28.4%. Notably, the quarter wasn't just about numbers. J&J reported compelling 5-year trial results for its multiple myeloma immunotherapy—an encouraging sign in the fight against a challenging cancer. The company also set an ambitious goal: to become the global leader in oncology by 2030, with a target of over $50 billion in cancer drug sales. With a potential $5 billion peak opportunity in bladder cancer and a strong pipeline aimed at offsetting losses from aging blockbusters, J&J is signaling that real innovation is back at the forefront. Breaking Free from the Margin Squeeze While markets often reward margin expansion, Johnson & Johnson looks especially well-positioned to benefit going forward. In addition to raising full-year earnings guidance, the company also delivered positive updates on cost pressures— halving its expected tariff impact from $400 million to $200 million and projecting a $1.1 billion tailwind from favorable currency shifts as the U.S. dollar weakens. The reduced tariff burden is primarily attributed to the MedTech division, which is more exposed to global supply chains and international manufacturing than the pharmaceutical segment. That's a clear tailwind for margins and future profitability. It's also important to note how strategic portfolio decisions have helped set the stage for this improvement. The 2023 spin-off of Kenvue—essentially the entire Consumer Health business—removed a lower-margin segment from the mix, sharpening J&J's focus on higher-margin areas. This move highlights the company's commitment not only to defending margins but also to actively growing them. In today's market, stability alone isn't enough—investors are looking for real margin expansion, and Johnson & Johnson seems intent on delivering. Analysts have responded by raising their EPS estimates for 2025 and 2026 by about 2% compared to before Q2 earnings. They now expect full-year EPS in 2025 to hit $10.86 —an 8.7% increase from last year—and to reach $11.34 in 2026, representing an annual growth rate of 4.4%. Reasonable Valuation with Growth on the Horizon Johnson & Johnson is a vast, stable, and diversified company, so its valuation tends to reflect relative stability rather than wild growth. Looking at its forward earnings multiple, currently around 15.5x, it's basically in line with the five-year average. This is well above the lows seen earlier this year, when it traded as low as 11x forward earnings in January. To me, this suggests the valuation isn't necessarily cheap, but it's reasonable. Comparing J&J's current earnings multiples over the last twelve months to its main peers, the 17.5x P/E ratio sits close to the sector average. Except for Merck & Co. (MRK), J&J is actually one of the more discounted names in the group. Finally, with a dividend yield of almost 3%, the stock no longer appears exuberant, and the yield isn't particularly compelling—especially when compared to the 10-year U.S. Treasury yield. However, J&J's payout ratio is typically safe, at around 50% of earnings, which helps build shareholder trust. Additionally, the market is now anticipating a more positive growth trajectory following the recent upward revisions to guidance, both last quarter and earlier this year. Is JNJ Stock a Buy, Hold, or Sell? Wall Street sentiment on Johnson & Johnson remains mixed, with more caution than conviction among analysts. Of the 19 analysts who have issued ratings over the past three months, nine are bullish, while the remaining ten are neutral. The average price target stands at $176.35, suggesting a modest upside of approximately 4.3% from the current share price. Johnson & Johnson Positioned for Consistent Alpha Generation Johnson & Johnson has, in my view, successfully restored market confidence in both its innovation pipeline and cost discipline—key pillars that could drive renewed growth and support reliable shareholder returns for decades to come. For long-term investors, initiating a position now is essentially a bet on a proven dividend combined with steady capital appreciation—an attractive formula that has historically outperformed the broader market. While the stock appears fairly valued at current levels, it offers compelling potential for compounding returns and consistent alpha generation in the years ahead.

Top Research Reports for NVIDIA, Netflix & Goldman Sachs
Top Research Reports for NVIDIA, Netflix & Goldman Sachs

Yahoo

time9 hours ago

  • Yahoo

Top Research Reports for NVIDIA, Netflix & Goldman Sachs

Friday, July 25, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp. (NVDA), Netflix, Inc. (NFLX), and The Goldman Sachs Group, Inc. (GS), as well as a micro-cap stock, AMREP Corp. (AXR). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today's research reports here >>> Ahead of Wall Street The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning. You can read today's AWS here >>> Pre-Markets Moderate in the Green for Another Up-Week NVIDIA's shares have outperformed the Zacks Semiconductor - General industry over the past year (+54.7% vs. +45.3%). NVIDIA is benefiting from the strong growth of artificial intelligence (AI) and high-performance, accelerated computing. The growing demand for generative AI and large language models using graphics processing units (GPUs) based on NVIDIA's Hopper and Blackwell architectures is aiding data center revenues. However, a limited supply of Blackwell GPUs could hinder its ability to meet demand. Rising costs associated with the production of more complex AI systems will hurt margins. (You can read the full research report on NVIDIA here >>>) Shares of Netflix have outperformed the Zacks Broadcast Radio and Television industry over the past year (+87.0% vs. +66.6%). Netflix delivered strong second-quarter results with earnings of $7.19 per share (beating estimates by 1.7%) and revenue of $11.07 billion (up 16% YoY). The quarter was highlighted by Squid Game S3 becoming the company's sixth biggest season ever with 122M views. Operating income surged 45% to $3.8 billion with margins expanding to 34% from 27% last year, driven by price increases and low churn rates. Netflix raised its full-year 2025 revenue guidance to $44.8-$45.2 billion and increased operating margin targets to 29.5%. (You can read the full research report on Netflix here >>>) Goldman Sachs' shares have outperformed the Zacks Financial - Investment Bank industry over the past year (+44.1% vs. +39.8%). The company's second-quarter 2025 results benefited from solid growth in the Global Banking & Markets division. Its refocus on the core strengths of investment banking (IB) and trading businesses through restructuring, along with acquisitions and expansion in private equity credit, is expected to boost global presence and diversify revenues. However, given the current geopolitical concerns, Goldman's high dependence on overseas revenues is worrisome. Also, the company's rising expenses due to ongoing investments in technology are concerning. (You can read the full research report on Goldman Sachs here >>>) Shares of AMREP have outperformed the Zacks Real Estate - Development industry over the past year (+2.7% vs. -14.1%). AMREP's net income surged 246.5% to $8.8 million for the nine months ended Jan. 31, 2025, with earnings per diluted share rising from $0.48 to $1.64. Home sales revenue grew 93.3% to $18.4 million, supported by strong demand in New Mexico, with 101 homes in production. However, elevated mortgage rates and affordability concerns may pressure future growth. AMREP faces risks from land sale concentration, project delays, and declining investment asset sales, impacting growth sustainability. (You can read the full research report on AMREP here >>>) Other noteworthy reports we are featuring today include AstraZeneca PLC (AZN), Gilead Sciences, Inc. (GILD), and Snap Inc. (SNAP). Mark VickerySenior Editor Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read NVIDIA (NVDA) Rides on Strong Adoption of GPUs, Partnerships Netflix (NFLX) Rides on Subscriber Growth, Original Content Strength in IB Business Aids Goldman (GS) Amid Cost Woes Featured Reports Key Drugs Aid AstraZeneca (AZN) Sales, Pipeline StrongAstraZeneca's key drugs like Lynparza, Tagrisso, Imfinzi and Farxiga should continue to drive sales. Per the Zacks analyst, its pipeline is strong, with pivotal data readouts lined up. HIV Franchise Fuel Gilead (GILD) Amid Oncology ChallengesPer the Zacks analyst, Gilead's strong momentum in HIV franchise and Liver disease franchise drive growth for the company. However, the Cell therapy franchise is facing challenges. Strategic Investments, Acquisitions Aid California Water (CWT)Per the Zacks analyst, California Water's infrastructure investments should help it provide reliable services. It gains from the expansion of operations through acquisitions and organic activities. Kirby (KEX) Benefits From Share Buyback Amid Rising ExpensesPer the Zacks analyst, rewarding shareholders through share buybacks boosts investor confidence and positively impacts Kirby's bottom line. Rising expenses continue to act as a concern. Subscriber Strength Aids America Movil (AMX) Amid Tariff WoesPer the Zacks analyst, increasing user count and widespread revenue growth across all business units and regions are driving America Movil's performance. U.S.-imposed tariff uncertainty concerns. Casey's (CASY) Grocery & General Merchandise Unit to Fuel Sales Per the Zacks analyst, expanded assortment of Grocery & General Merchandise category are likely to fuel Casey's sales. The segment recorded same-store sales growth of 1.8% in the fourth-quarter. Walgreens (WBA) Gains on U.S. Retail Growth, New LaunchesThe Zacks analyst is upbeat on Walgreens' U.S Retail Pharmacy's turnaround, driven by new strategic merchandising initiatives and omni-channel expansion. Recent product launches also seem strategic. New Upgrades EchoPark Segment Strength Aids Sonic Automotive (SAH)EchoPark posted record Q2 income, emerging as Sonic's key growth driver. The Zacks analyst sees its data-driven inventory strategy and refined business model powering continued momentum ahead. Tenet (THC) to Gain From USPI Strength & Strategic DivestmentsPer the Zacks analyst, the rising surgical cases in the USPI business will drive Tenet Healthcare's performance, while divestments will help allocate capital to higher-return investments. Solid User Growth & Premium Content Demand Aids Snap (SNAP)Per the Zacks analyst, Snap benefits from an improving user growth driven by strong adoption of Augmented Reality (AR) Lenses and demand for premium content including Shows. New Downgrades Core Lab's (CLB) Revenue Hurt by Ongoing Sanction & TariffsThe Zacks analyst believes that despite partial recovery in assay services in Q2, uncertainty still looms over Core's revenue due to ongoing geopolitical conflicts and sanctions & tariffs. Weyerhaeuser (WY) is Hurting From Macro Risks & High CostsPer the Zacks analyst, Weyerhaeuser's prospects are hurting from the ongoing global market uncertainties and elevated cost and expense structure. A pause on China export concerns its sales volume. High Costs & Macro Woes Ail BJ's Restaurants (BJRI) ProspectsPer the Zacks analyst, BJ's Restaurants operations are likely to be affected by food inflation and potential tariff-related margin pressures. Also, an uncertain macro environment pose concerns. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Goldman Sachs Group, Inc. (GS) : Free Stock Analysis Report AstraZeneca PLC (AZN) : Free Stock Analysis Report Netflix, Inc. (NFLX) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report NVIDIA Corporation (NVDA) : Free Stock Analysis Report Snap Inc. (SNAP) : Free Stock Analysis Report AMREP Corporation (AXR): Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research

Mayor Brandon Johnson pledges no push for property tax hike after CFO recently called one ‘likely'
Mayor Brandon Johnson pledges no push for property tax hike after CFO recently called one ‘likely'

Chicago Tribune

time15 hours ago

  • Chicago Tribune

Mayor Brandon Johnson pledges no push for property tax hike after CFO recently called one ‘likely'

Mayor Brandon Johnson is now ruling out seeking a property tax hike in his upcoming budget proposal, an apparent shift in course for his administration after a top city official said earlier in the week that they probably would do so. On Friday, Johnson said he will instead try again to tax the city's wealthiest residents and corporations. He added that he has 'a number' of ideas for progressive revenue, but did not answer when asked to share them. 'The ultra-rich in this city and this state have an opportunity to do a better job in investing in our infrastructure, investing in community safety,' he said. Johnson told the Tribune that 'nothing has changed' when asked about the apparent abrupt switch-up during a news conference. The mayor's attempts to raise property taxes to balance this year's budget were roundly rejected by aldermen. But he said he isn't turning away from property taxes to close the 2026 budget hole because he's worried he doesn't have the votes. 'We've always made it very clear from the very beginning that we are going to invest in people and use progressive revenue to ensure that we build the safest, most affordable big city in America,' he said. Just Tuesday, Chicago's Chief Financial Officer Jill Jaworski said 'it is likely that that will be part of the package' when asked about the mayor calling for a 2026 property tax increase. But the mayor delivered a clear rejection of the idea Thursday. 'I will not be proposing a property tax increase in my budget. I'm going to continue to work hard to find progressive revenue,' he told ABC-7 Chicago. The mayor similarly did not specify Thursday to ABC-7 what new taxes and other revenue-raisers he hopes to rely on to balance the city's budget. He also said it was too early to discuss potential furloughs and layoffs, adding 'our workforce is what makes our city strong.' The 2026 budget fight will begin in earnest after Labor Day. Johnson, who campaigned promising to not raise property taxes, proposed last year that the city raise them by $300 million to help close a budget gap near $1 billion. Aldermen rejected the plan in an unprecedented 50-0 vote. The mayor's administration then tried to negotiate several smaller property tax hikes with aldermen, but was rejected each time. The City Council's decision, alongside Johnson's opposition to city service and workforce cuts, resulted in a compromise to balance the budget with a fleet of smaller taxes and fees. The largest was a roughly $130 million hike to the personal property lease tax on cloud computing services, a move that affected software services, including many that businesses rely upon. Johnson notably failed in an earlier effort to tax the rich in 2023 when the 'Bring Chicago Home' plan lost in a citywide referendum. The proposal would have hiked taxes on real estate transfers over $1 million to raise money to pay for homelessness services. Many aldermen fear the sort of kitchen-sink approach they used to land the budget last year will be harder to use this year. Several easier-to-tap options have been exhausted, and the city's fiscal challenges have only grown as federal funding cuts threaten the city's already precarious financial position. Johnson's top budget officials have long described property taxes as an effective way to bring in predictable, long-term revenue and stabilize the city's budget. But in ruling out property taxes as part of the package this fall, the mayor may very well have sensed a trial balloon had popped after several aldermen quickly criticized the idea this week.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store